PandoraHaggai
2022-08-16

$Unity Biotechnology(UBX)$One of the reasons for the rise in healthcare spending comes down to longevity. Aging and staying alive longer creates a lot of problems for people. The forefront of this could be newly IPO’d  Unity Biotechnology Inc (NASDAQ:UBX).

Unity is a very early stage clinical biotech — the opposite of previously mentionedMorphoSys.But its approach seems worthy of a portfolio position. UBX is developing so-called senolytic therapies to treat age-related diseases. These medicines selectively induce the death of senescent cells. Senescent cells are those that have stop dividing. For age-related disorders, this is fertile ground for treatment. By blocking these cells, Unity hopes to halt various age-related diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment